A fusion protein derived from Moraxella catarrhalis and Neisseria meningitidis aimed for immune modulation of human B cells.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Moraxella IgD-binding protein (MID) is a well characterized trimeric autotransporter that specifically targets the IgD of B cells. We fused the membrane anchor of the meningococcal autotransporter NhhA with the IgD-binding region of MID (aa 962-1200) to create a chimeric protein designated as NID. The aim was to use this specific targeting to provide a better vaccine candidate against meningococci, in particular serogroup B by enhancing the immunogenicity of NhhA. NID was thereafter recombinantly expressed in E. coli. The NID-expressing E. coli bound to peripheral B lymphocytes that resulted in cellular activation. Furthermore, we also successfully expressed NID on outer membrane vesicles, nanoparticles that are commonly used in meningococcal vaccines. This study thus highlights the applicability of the menigococcal-Moraxella fusion protein NID to be used for specific targeting of vaccine components to the IgD B cell receptor.


  • Oindrilla Mukherjee
  • Birendra Singh
  • Burcu Bayrak
  • Ann-Beth Jonsson
  • Matthias Mörgelin
  • Kristian Riesbeck
Enheter & grupper

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Mikrobiologi inom det medicinska området
Sidor (från-till)2223-2227
TidskriftHuman Vaccines & Immunotherapeutics
Utgåva nummer9
StatusPublished - 2015
Peer review utfördJa


Ingen tillgänglig data